• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » AbbVie and Galapagos extend GLPG0634 collaboration

AbbVie and Galapagos extend GLPG0634 collaboration

June 10, 2013
CenterWatch Staff

Galapagos, which specialized in novel modes-of-action, and AbbVie have extended their GLPG0634 clinical development collaboration to include Crohn's disease. Galapagos will fund and complete a phase II program in Crohn's, designed to facilitate rapid progression into phase III.  Upon successful completion of the study, expected in the second quarter of 2015, AbbVie will pay Galapagos $50 million. 

 AbbVie will be responsible for funding and performing clinical development beyond phase II and completing regulatory and commercialization activities.

Galapagos will start an innovative 20-week phase IIa/b study with GLPG0634 in 180 patients suffering from Crohn's by early 2014.  The study will measure both induction of disease remission and early maintenance of its beneficial effects in Crohn's, and is expected to read out topline results.  This phase II study will be performed in parallel with the phase IIb study in rheumatoid arthritis (RA).

"AbbVie supports the start of this innovative study in Crohn's disease with GLPG0634.  Our experience within gastroenterology, combined with a novel alternative treatment for this disease, may provide a greater benefit to patients in the future," said Scott Brun, M.D., vice president of pharmaceutical development at AbbVie.

"Galapagos and AbbVie are moving forward with GLPG0634, expanding the scope of the development program into inflammatory bowel disease,” said Onno van de Stolpe, chief executive officer of Galapagos. “Galapagos is in a strong financial position to fund the Crohn's program, in addition to the phase IIb program with GLPG0634 in RA and our other proprietary clinical and pre-clinical programs.”

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • TechInnovation-360x240.png

    Pace of Technology Innovation in Trials Could Slow After Pandemic Eases

  • AskTheExperts-360x240.png

    Ask the Experts: Certifying and Maintaining Copies of Original Source Documents

  • Resources-360x240.png

    Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

  • FocusinRed-360x240.png

    Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing